ModifiedUnitedHealthcarePolicy CS007OH.D

Bariatric Surgery (for Ohio Only)

Medical policy governing coverage and medical necessity criteria for bariatric and metabolic surgery for UnitedHealthcare members in Ohio.

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery (for Ohio Only)

Policy CodePolicy CS007OH.D

Change TypeRemoved 'proven and medically necessary' languageeditorial link update

Effective DateMay 1, 2025

Next Review DateN/A

Key ActionDetermine medical necessity using InterQual CP: Bariatric or Metabolic Surgery (and Adolescent) and request prior authorization when InterQual criteria apply.

SourceLink

POLICY UPDATE CHANGES

Removed language listing multiple bariatric surgical procedures as proven and medically necessary (including adjustable gastric band, biliopancreatic diversion with duodenal switch, RYGB, sleeve gastrectomy, revisional procedures, and related band removals).

Updated reference link to reflect the current policy title for Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Ohio Only).

Ohio-onlyjurisdiction limited to

InterQualexternal criteria referenced

>=11procedures unproven

6 moIGB therapy duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Use 43775coding note

Coverage and Medical Necessity Criteria

Medical necessity — InterQual referenced

Covered when ALL of the InterQual Bariatric or Metabolic Surgery criteria (and Adolescent criteria when applicable) are met:

InterQual criteria: Member meets InterQual CP: Bariatric or Metabolic Surgery (or Adolescent) criteriasee InterQual

InterQual referenced for full clinical inclusion/exclusion

Coverage stance by procedure/device

Evidence summaries and coverage implications for investigational or established procedures:

Bariatric artery embolization (BAE): BAE/LGA embolization is investigational: existing evidence consists of small RCTs and case series showing modest short-term weight loss with safety signals and high heterogeneity; larger randomized trials with long-term follow-up are needed.evidence insufficient

Reddy et al. 2020 RCT and systematic reviews show limitations and call for larger studies.

Gastric electrical stimulation (GES): GES is investigational/experimental: early feasibility and prospective series report variable weight loss and acceptable short-term safety but lack robust randomized data and long-term outcomes to support routine coverage.evidence insufficient

Phase 1 and multicenter prospective series show preliminary safety but call for larger RCTs.

Intragastric balloons (IGB): IGBs produce short-term clinically significant weight loss versus diet/exercise but have mixed long-term durability and meaningful rates of early intolerance and device-related adverse events; evidence supports conditional, time-limited use with multidisciplinary follow-up.short-term benefit only

Pivotal RCTs (e.g., REDUCE, Spatz) and systematic reviews demonstrate short-term efficacy; long-term maintenance uncertain.

BPD/DS (biliopancreatic diversion/duodenal switch): BPD/DS yields substantial and durable weight loss and comorbidity improvement in cohort and long-term series but has higher risk of nutritional deficiencies and longer hospital stay compared with restrictive procedures; consider intensive long-term monitoring when used.consider long-term monitoring for deficiencies

Long-term series report durable efficacy but notable nutritional complications.

Evidence summaries and coverage-relevant conclusions

Evidence-summary based stance for procedures/devices in this document portion:

Intragastric Balloon (IGB): IGB provides short-term weight loss; dual-balloon systems (REDUCE) showed greater weight loss than diet alone but studies have high loss-to-follow-up and limited long-term data; adverse events include abdominal symptoms, ulcers, deflation, and early removals; insufficient evidence for long-term safety/efficacy.

Refs: REDUCE pivotal trial, Spatz and systematic reviews.

Laparoscopic Greater Curvature Plication (LGCP): LGCP yields initial weight loss but comparative studies and meta-analyses show inferior durability and higher adverse events versus LSG; weight regain and revisional surgery rates are concerning.

Refs: Park & Kim 2023; Tang 2015 meta-analysis.

Mini/One-Anastomosis Gastric Bypass (MGB/OAGB): OAGB/MGB demonstrates comparable or greater short- and medium-term weight loss versus RYGB and LSG in some studies but may have higher rates of GERD, diarrhea/steatorrhea and nutritional disorders; long-term safety beyond five years requires further characterization.

Refs: comparative studies noting higher GERD and malabsorptive effects.

Evidence-based stance summaries by device/procedure

Evidence summaries and implied coverage considerations by modality (no formal algorithm provided in these chunks):

SADI-S / SADS: Comparative cohort data vs RYGB at 18 months showed similar weight loss but procedure-specific differences in complications and need for further study; consider SADI-S within research or when expertise and long-term follow-up available.

Comparative cohort data indicate similar early outcomes; larger RCTs and longer follow-up needed.

Stomach aspiration therapy (AspireAssist): Small RCTs and extensions show meaningful short- and mid-term weight loss (≈17–18% TWL sustained to 4 years in limited cohorts) with pooled SAE ~4%; consider only with careful patient selection and informed consent regarding uncertain long-term behavioral effects.

Meta-analyses and PATHWAY follow-up report sustained weight loss but limited sample sizes.

Transoral endoscopic devices (TPS, endoscopic bypass sleeves): Feasibility and small trials report weight loss and QoL improvements but evidence limited by small size and short follow-up; safety signals and device removals reported—use limited to research or specialized programs.

Intragastric Balloon (IGB) — conditional coverage when part of multidisciplinary care

Covered when ALL of the following are met

IGB candidate criteria: Patient has obesity and has failed conventional weight-loss strategies (documented attempts at supervised diet/behavior modification and, when appropriate, pharmacotherapy); the device is used as a temporary adjunct to a multidisciplinary lifestyle program; the provider can deliver or arrange multidisciplinary follow-up to monitor tolerance, adverse events, and post-removal maintenance; informed consent documents device-specific risks and time-limited nature of therapy.device in situ ≤ 6 months (FDA)

AGA and ASGE recommend IGB plus lifestyle modification; FDA-approved IGBs have a maximum 6-month placement period; prophylactic PPI and antiemetic strategies recommended.

Duodenal-Jejunal Bypass Liner (DJBL/EndoBarrier) — investigational/limited due to safety

Coverage stance based on evidence and safety

DJBL evidence summary: DJBL/EndoBarrier demonstrates short-term weight loss and some glycemic improvements but is associated with high rates of adverse events (including hepatic abscess, gastrointestinal hemorrhage), frequent early explantation, and weight regain after removal; evidence quality is limited and safety concerns preclude routine long-term use.use limited/research only

NICE and systematic reviews recommend use only in research; CE mark removed for EndoBarrier.

Bariatric surgery eligibility — standard guideline thresholds

Eligibility recommendations from professional societies:

Standard adult surgical eligibility: MBS is recommended for individuals with BMI ≥ 35 kg/m2 (ASMBS/IFSO update recommends ≥35 regardless of comorbidities) and should be considered for individuals with metabolic disease and BMI 30–34.9 kg/m2; other societies (AACE/ASMBS/AACE/ACE) list BMI ≥40 or BMI ≥35 with comorbidities as thresholds and advise adjusting BMI thresholds for certain ethnicities.BMI thresholds as stated in source guidelines

Guidelines recommend multidisciplinary evaluation and comprehensive preoperative assessment.

Adolescent eligibility: Adolescents: use pediatric/adolescent thresholds (e.g., Class II: BMI ≥ 35 or ≥120% of 95th percentile with clinically significant disease; Class III: BMI ≥ 40 or ≥140% of 95th percentile) and require multidisciplinary evaluation by experienced centers; Tanner stage and near-final height considerations per Endocrine Society and ASMBS pediatric guidelines.see pediatric thresholds

AAP and Endocrine Society guidance specify age/percentile criteria and multidisciplinary requirements.

Coverage criteria for bariatric and endoscopic procedures

Covered when ALL of the following policy-aligned criteria are met (per specialty society guidance and pediatric/adolescent guidelines):

Established adult bariatric procedures: Established procedures (e.g., sleeve gastrectomy, Roux-en-Y gastric bypass) have long-term outcome data supporting durable weight loss and comorbidity improvement and are considered standard surgical options when patient selection and multidisciplinary evaluation criteria are met.

ASMBS and other specialty society position statements support SG and RYGB as established procedures.

Temporary intragastric balloon use: Temporary intragastric balloon therapy is FDA-approved for up to six months and may be covered as an adjunct to a supervised diet and behavior modification program with documented multidisciplinary follow-up and informed consent regarding device-specific risks and potential need for early removal.device in situ ≤ 6 months

ASMBS and FDA statements recommend multidisciplinary follow-up and counseling.

Adolescent MBS candidacy:

NICE: research-only and conditional procedures

Procedures/devices noted by NICE with restricted use

NICE research-only procedures: EndoBarrier (duodenal-jejunal bypass liner) and swallowable gastric balloons: current evidence is limited and inadequate; NICE recommends use only in the context of research with detailed patient selection, complication reporting, and regulatory/ethical approvals.research-only

NICE notes EndoBarrier no longer has CE mark; non-CE devices only in clinical investigations.

NICE: ESG

NICE statement on ESG

Endoscopic sleeve gastroplasty (ESG): NICE (2024): evidence indicates ESG is safe in the short and long term and, when combined with lifestyle interventions, results in weight loss for people with BMI > 30 kg/m2.BMI > 30 kg/m2

NICE suggests ESG use in selected patients combined with lifestyle programs.

AASM and Thoracic Society

Professional society recommendations relevant to referral and therapy selection:

AASM referrals for OSA patients with obesity: AASM recommends clinicians discuss referral to a bariatric surgeon for adults with OSA and obesity (class II/III, BMI ≥ 35) who are intolerant of PAP, and to consider referral to sleep or bariatric surgeons for selected patients based on BMI and PAP tolerance.BMI thresholds as per AASM guidance

AASM task force recommendations guide referral decisions for OSA patients.

Thoracic Society and general guidance: Thoracic Society guidance recommends initial conservative therapies (diet, exercise, behavioral) and considers pharmacologic therapy or bariatric surgery for selected patients with OSA and overweight/obesity.

Guidance intended to support referral and therapy selection.

VA/DoD

VA/DoD guideline suggestions

VA/DoD suggestions for bariatric surgery and devices: VA/DoD suggests offering metabolic/bariatric surgery for adults with BMI ≥ 40 or BMI ≥ 35 with obesity-associated conditions; suggests considering MBS for BMI ≥ 30 with type 2 diabetes; suggests intragastric balloons for patients with BMI ≥ 30 prioritizing short-term (up to six months) weight loss as adjunct to lifestyle intervention.BMI thresholds as specified

VA/DoD acknowledges insufficient evidence for some populations (e.g., age >65) for certain procedures.

FDA: device indications (informational)

FDA device labeling informational statements (informational only):

FDA device indications: ORBERA is indicated for adults with BMI ≥ 30 and ≤ 40 as an adjunct to supervised diet and behavior modification with a maximum placement period of six months; LAP-BAND labeling indicates use for adults with BMI ≥ 40 or BMI ≥ 35 with comorbidity (and earlier labeling referencing BMI ≥ 30 with comorbidity); TransPyloric Shuttle is indicated for BMI 35.0–40.0 or 30.0–34.9 with comorbidities for up to 12 months.device-specific BMI ranges

FDA approvals are informational and not sole basis for coverage determinations.

Bariatric surgical and endoscopic interventions target durable weight reduction and improvement in obesity-related comorbidities. Coverage determinations for these interventions are guided by clinical criteria referenced to InterQual (see InterQual CP: Bariatric or Metabolic Surgery and Adolescent criteria where applicable) and by the evidence summaries for specific procedures and devices. Several procedures and devices described in this policy are considered unproven and not medically necessary for treatment of obesity because current evidence is insufficient to demonstrate long-term safety or durable efficacy (examples include bariatric artery embolization, gastric electrical stimulation, gastrointestinal liners, intragastric balloons, laparoscopic greater curvature plication, mini-gastric bypass/OAGB, single-anastomosis duodenal switch/SADS, stomach aspiration therapy, transoral endoscopic procedures including TPS and ESG, and vagus nerve blocking).

The EndoBarrier duodenal-jejunal bypass liner is not approved by the U.S. Food and Drug Administration and is limited under federal law to investigational use only; an IDE was issued for EndoBarrier studies. Use of EndoBarrier outside of an approved investigational protocol is inconsistent with federal regulatory status and is considered investigational in this policy.

Several procedures described in this policy are investigative or lack robust, long-term randomized controlled trial evidence. Examples include bariatric artery embolization (small RCTs and case series with short follow-up), many forms of gastric electrical stimulation (early feasibility and cohort studies), and some intragastric balloon variants (RCTs and systematic reviews demonstrating short-term benefit but limited long-term durability and high loss-to-follow-up). Additional well-designed RCTs with longer follow-up are needed to support routine coverage.

Procedures and devices with limited long-term randomized evidence or concerning adverse-event profiles may be restricted or considered investigational. Examples include certain intragastric balloon systems with uncertain durability and device-specific adverse events, laparoscopic greater curvature plication which has shown inferior durability and higher adverse events than sleeve gastrectomy in pooled analyses, mini/one‑anastomosis gastric bypass variants with higher GERD and malabsorptive complications, and SADI‑S where heterogeneous observational data suggest efficacy but lack large RCT confirmation and raise malabsorption concerns.

Published case series and reviews of duodenal‑jejunal bypass liners (DJBL/EndoBarrier) report a high frequency and, in some instances, severe adverse events; these findings have led authors to conclude that use of prototype DJBL devices for periods longer than one year is precluded due to safety concerns.

Long-term implantation of DJBL/EndoBarrier is not supported by available safety data. Trials and systematic reviews document frequent adverse events (including hepatic abscess and gastrointestinal hemorrhage), high rates of device‑related complications, and substantial weight regain after explantation, indicating insufficient evidence of sustained safety and efficacy for prolonged device use.

Bariatric surgery is not appropriate for certain populations. Specifically, surgery should not be performed in preadolescent children, in adolescents who are currently pregnant or breastfeeding (or plan pregnancy within two years of surgery), or in patients with unresolved substance abuse, active eating disorders, or untreated psychiatric illness. Adolescent candidates require multidisciplinary evaluation, psychological assessment, demonstrated ability to adhere to healthy dietary and activity habits, and care at an experienced bariatric center capable of long-term follow-up.

NICE guidance discourages routine use of EndoBarrier and swallowable gastric balloons outside research settings and notes that EndoBarrier lost its CE mark; swallowable balloons are recommended only in the context of formal research. Where NICE has concluded evidence is limited, use should be restricted to research with defined governance, consent, and complication reporting.

A prior version of this policy included language listing several bariatric surgical procedures as “proven and medically necessary.” That statement was removed effective 05/01/2025, and the policy language was updated to reflect current evidence-based positions and references.

The procedures enumerated in the policy’s unproven list are explicitly identified as not medically necessary for routine treatment of obesity because current evidence is insufficient to establish long-term efficacy and safety. Requests for these procedures may be denied absent convincing supporting evidence or an approved research context.

Gastrointestinal liners such as the EndoBarrier are considered investigational for weight loss and are not FDA‑approved for use in the United States. Federal regulatory status and available safety evidence support classification of EndoBarrier as investigational in this policy.

Bariatric artery embolization (BAE/LGA embolization) is investigational due to limited evidence. Existing small randomized trials and case series report modest short‑term weight loss but are limited by small sample sizes, single‑center designs, heterogeneity of techniques, and uncertainty about long‑term safety and effectiveness; larger, long‑term RCTs are required before routine coverage can be recommended.

Endoscopic approaches — including endoscopic sleeve gastroplasty (ESG), the TransPyloric Shuttle (TPS), and other transoral devices — lack sufficient high‑quality, long‑term randomized evidence to be considered equivalent to established bariatric surgeries. Systematic reviews and RCTs show short‑term weight loss versus lifestyle modification but uncertainty remains about long‑term durability and comparative effectiveness.

Multiple DJBL/EndoBarrier studies report frequent and sometimes serious adverse events with device use and high rates of weight regain after removal; combined with limited long‑term comparative data, this evidence does not support routine long‑term implantation of DJBL/EndoBarrier for obesity treatment.

NICE has identified several procedures with limited evidence (for example, duodenal‑jejunal bypass liners/EndoBarrier, swallowable gastric balloons, and SADI‑S at the time of guidance) and recommends their use only in research contexts or with special arrangements for governance, consent, and audit; such limitations indicate restricted routine adoption outside clinical studies.

NICE’s interventional guidance explicitly limits use of swallowable gastric balloons to research settings because evidence on efficacy is inadequate; routine clinical use outside approved research is discouraged.

Although this policy section does not restate a comprehensive list of explicit not‑medically‑necessary statements, removal of prior “proven and medically necessary” language on 05/01/2025 represents a deliberate change in coverage rationale and reflects the policy’s current, evidence‑based stance toward listed procedures.

Coding, BMI Thresholds, and Device Indications

Applicable CPT CodesCPT

0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
43290	Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon.
43291	Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only.

1–10 of 30

1/3

BMI categories — standard ranges

UnderweightBMI < 18.5 kg/m2

Normal weightBMI 18.5–24.9 kg/m2

OverweightBMI 25–29.9 kg/m2

Obesity Class IBMI 30–34.9 kg/m2

Obesity Class IIBMI 35–39.9 kg/m2

Obesity Class IIIBMI ≥ 40 kg/m2

Transpyloric Shuttle (TPS) BMI indications

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization guided by InterQual

Prior authorization guided by InterQual — Medical necessity determinations for bariatric and metabolic procedures (including adolescents) are based on InterQual CP: Bariatric or Metabolic Surgery and InterQual CP: Bariatric or Metabolic Surgery (Adolescent) when applicable. Providers should follow InterQual findings for coverage decisions.

Documentation Required

Device regulatory status confirmation

Providers should verify and document the regulatory status and labeled indications of any bariatric device prior to submission. Document the exact device model, FDA clearance/approval or investigational (IDE/clinical trial) status, and the manufacturer-recommended BMI range or other label-based contraindications.

Document device model and manufacturer
Document FDA status (PMA, 510(k), IDE, investigational)
Document labeled BMI/indication ranges

Clinical Background and Evidence Highlights

Obesity is defined by body mass index (BMI) and is associated with multiple comorbidities including hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, and some cancers. Screening for and referral to intensive behavioral interventions is recommended for adults with BMI ≥30 kg/m2; surgical and endoscopic interventions are considered when guideline thresholds and individualized assessment (including multidisciplinary evaluation) support procedural treatment.

Evidence summaries across device and procedure types inform coverage‑relevant conclusions: intragastric balloons and dual‑balloon systems demonstrate statistically significant short‑term weight loss in randomized trials but have limited long‑term durability and notable device‑specific adverse events; SADI‑S and some malabsorptive procedures show promising sustained weight loss in observational series but lack large randomized comparative trials; aspiration therapy and implanted neuroregulators have variable quality evidence and require further high‑quality trials to define long‑term benefits and risks. These evidence assessments form the basis for the policy’s investigational or conditional coverage designations.

Key Definitions and Device Descriptions

BMI definition and categories

BMI definitionWeight in kilograms divided by height in meters squared (kg/m2)

Adult category: UnderweightBMI < 18.5 kg/m2

Adult category: NormalBMI 18.5–24.9 kg/m2

Adult category: OverweightBMI 25–29.9 kg/m2

Adult category: Obesity Classes I–IIIClass I 30–34.9; Class II 35–39.9; Class III ≥ 40 kg/m2 (Class III highlighted as most actionable)

Obstructive Sleep Apnea (OSA) severity definitions

Mild OSA

Policy Revision History

2026-04-01policy_updateLatest

Most recent policy update recorded (Instructions for Use and referencing governing criteria sources).

2025-05-01content_change

Removed prior statements listing several bariatric surgical procedures as 'proven and medically necessary'.

As part of the May 1, 2025 policy update, language that previously described multiple bariatric surgical procedures as “proven and medically necessary” was removed. This clarification is recorded in the policy history and represents a material change reflecting updated alignment with current evidence and guidance.

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery (for Ohio Only)

Policy CodePolicy CS007OH.D

Change TypeRemoved 'proven and medically necessary' languageeditorial link update

Effective DateMay 1, 2025

Next Review DateN/A

Key ActionDetermine medical necessity using InterQual CP: Bariatric or Metabolic Surgery (and Adolescent) and request prior authorization when InterQual criteria apply.

SourceLink

On This Page

Single-Anastomosis Duodenal-Ileal Switch (SADI-S/SADS): SADI-S/SADS shows durable weight loss and high comorbidity remission in observational series, but evidence is heterogeneous and lacks large RCTs; malabsorption risks warrant long-term follow-up.

Refs: systematic reviews and cohort studies reporting %EWL ranges.

Stomach Aspiration Therapy (AspireAssist): Aspiration therapy yields meaningful short- and mid-term weight loss in low-quality and single-arm studies with pooled SAE rates around 4%; behavioral effects and comparative effectiveness remain uncertain and further RCTs are needed.

Refs: ECRI assessment and systematic reviews reporting sustained TWL to 4 years in limited samples.

Feasibility trials and single-arm series with short-term results.

Endoscopic Sleeve Gastroplasty (ESG): Systematic reviews and RCTs report ESG yields greater weight loss than lifestyle modification but less than surgical sleeve gastrectomy; SAEs are low-to-moderate (~2%); long-term comparative effectiveness and durability remain uncertain.

Hayes and multiple systematic reviews summarize ESG outcomes and limitations.

Vagus Nerve Blocking (vBloc/Maestro): Randomized sham-controlled trials showed greater weight loss versus sham at 12 months but pivotal trials did not meet prespecified coprimary efficacy objectives; longer-term durability uncertain—coverage should be considered experimental outside defined indications.

ReCharge and other RCTs with mixed results.

Gastrointestinal liners (EndoBarrier/DJBL): RCTs and case series show short-term weight loss and metabolic improvements but high adverse event rates (including hepatic abscess) and frequent weight regain after removal; routine clinical use is not supported pending improved safety and long-term data.

Multiple RCTs and observational series report high AE rates and explantation frequency.

Adolescents meeting pediatric/adolescent BMI percentile or absolute BMI thresholds per ASMBS/AAP/Endocrine Society, evaluated at a comprehensive metabolic and bariatric surgery center with adolescent expertise, and without contraindications (e.g., pregnancy, unresolved substance abuse, uncontrolled psychiatric illness) may be considered for MBS.

see pediatric thresholds

AAP and Endocrine Society guidance require multidisciplinary assessment and center expertise.

Revisional surgery: Reoperative bariatric surgery may be considered after multidisciplinary evaluation for insufficient weight loss, complications, or device/procedure failure; selection should document prior interventions, objective outcomes, and anticipated benefit given higher reoperation risk.

ASMBS Revision Task Force recommendations emphasize careful selection and documentation.

Primary adult indication (FDA)BMI 35.0–40.0 kg/m2

Alternate adult indication (FDA)BMI 30.0–34.9 kg/m2 with one or more obesity-related comorbid condition

Intended useTransPyloric Shuttle is intended as an adjunct to diet and behavior modification with up to 12 months treatment duration

Intragastric balloon (IGB) typical duration

Typical therapy duration6 months (standard insertion-to-removal interval for FDA-cleared intragastric balloons)

Adjunctive requirementIntended to be used in conjunction with diet, exercise, and behavioral counseling/multidisciplinary support

Regulatory noteFDA pivotal trials and professional society statements frame IGB as a temporary endoscopic tool with maximum placement period of six months

BMI thresholds for surgical consideration — examples and exceptions

Classic adult surgical thresholdBMI ≥ 40 kg/m2

Adult threshold with comorbidityBMI ≥ 35 kg/m2 with one or more severe obesity-related comorbid conditions

Consideration for metabolic diseaseConsider MBS for BMI 30–34.9 kg/m2 in patients with metabolic disease (per ASMBS/IFSO and AACE/ASMBS guidance)

Adolescent BMI thresholds for MBS candidacy (per cited guidelines)

Adolescent Class II candidacyBMI ≥ 35 kg/m2 or ≥ 120% of the 95th percentile for age/sex with clinically significant disease (e.g., T2D, IIH, severe OSA)

Adolescent Class III candidacyBMI ≥ 40 kg/m2 or ≥ 140% of the 95th percentile for age/sex

Pediatric endocrine/height requirementEndocrine Society: consider Tanner stage 4–5 and near-final adult height when evaluating adolescents for MBS

BMI — device-specific FDA labeling examples (ORBERA, LAP-BAND historical)

ORBERA (IGB) FDA labelingIndicated for adults with BMI ≥ 30 and ≤ 40 kg/m2 as adjunct to supervised diet and behavior modification; maximum placement period six months

LAP-BAND (historical PMA labeling)Approved for adults with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with one or more severe comorbid conditions; later labeling referenced BMI ≥ 30 with comorbidity in some approvals

Device documentation recommendationFor FDA-cleared devices, document device model, FDA approval/clearance status, and that use follows labeled BMI/comorbidity indications

Prior Authorization

IGB prior authorization expectation

Intragastric balloons (IGBs) have randomized controlled trial evidence demonstrating short-term clinically significant weight loss when used with diet and exercise counseling. Prior authorization is recommended to ensure appropriate candidate selection, documentation of prior conservative therapies, and plans for concomitant lifestyle intervention and follow-up.

Typical duration: up to 6 months (manufacturer/FDA labeling)
Document prior conservative therapy attempts and willingness to participate in supervised diet/behavior program

Prior Authorization

Prior authorization recommended for novel devices/procedures

Novel bariatric devices and procedures with limited long-term randomized controlled trial evidence (for example, some gastrointestinal liners, newer endoscopic devices, certain neurostimulation systems, and emerging techniques) should be subject to prior authorization review. Authorization should confirm that appropriate informed consent, device regulatory status, and multidisciplinary follow-up plans are in place.

Confirm enrollment in approved clinical trials when device is investigational
Require documentation of counseling on limited long-term safety/effectiveness

Prior Authorization

Prior authorization for implanted neuroregulators and similar devices

Implanted neuroregulators and similar systems (e.g., vBloc/Maestro, other vagal nerve or gastric electrical stimulators) require prior authorization review. Authorization should document prior conservative therapy failure, device model and FDA status, and a plan for device monitoring and management of expected adverse events.

Document prior conservative therapy attempts
Document device model and FDA/IDE status
Describe plan for long-term follow-up and management of device-related AEs

Prior Authorization

Prior authorization and multidisciplinary care requirement

Multidisciplinary evaluation may be required for certain device-based therapies (for example, intragastric balloon placement and EndoBarrier/DJBL). Prior authorization may request documentation of involvement from bariatric surgery, nutrition, and behavioral health specialists as part of pre-procedure assessment.

Include documentation of consultations (surgery, nutrition, behavioral health) when requested
Provide a coordinated care and follow-up plan

Prior Authorization

Center referral for adolescent MBS

Refer adolescents being considered for metabolic or bariatric surgery to a comprehensive metabolic and bariatric surgery center with adolescent expertise. The evaluation should involve the multidisciplinary team and consider patient and family needs.

Referral to an accredited center with adolescent bariatric experience
Document family involvement and assessment of psychosocial/social risk factors

Documentation Required

Verify device indications and regulatory status

Providers must document device model and FDA clearance/approval status (or investigational status) in the medical record and in prior authorization submissions. This includes devices such as ORBERA, LAP-BAND, TransPyloric Shuttle, OverStitch, and other branded systems.

List device trade name and model
Provide copy of FDA clearance/approval or indicate investigational/IDE status

Note

Use of criteria sources

UnitedHealthcare uses InterQual for primary medical/surgical criteria and ASAM for substance use determinations; follow InterQual determinations when available. If InterQual criteria are not applicable, UnitedHealthcare medical policies and coverage determination guidelines (as approved) may be used.

InterQual CP: Bariatric or Metabolic Surgery is primary criteria source
ASAM used for substance use assessments

Step Therapy

First-line therapy

First-line therapy must be documented prior to surgical consideration. Include prior attempts at dietary therapy, physical activity, behavior modification, and medication management, and evidence that these approaches were insufficient to achieve durable weight loss.

Document supervised diet/exercise programs and behavioral interventions
Document prior pharmacotherapy trials when applicable

Step Therapy

GERD conservative management before revision

For patients experiencing GERD after prior bariatric surgery, conservative management should be attempted before considering revisional surgery. Document trials of dietary and lifestyle modification, alcohol and smoking cessation, and use of acid‑reducing medications.

Document duration and response to lifestyle measures
Document trials of proton pump inhibitor or other acid-reducing therapy

Step Therapy

Step therapy for IGB

Step therapy considerations for intragastric balloon placement: document failure or contraindication to less invasive options and provide evidence of enrollment or planned enrollment in structured lifestyle and behavioral programs. Prior authorization may request prior attempted intensive medical/lifestyle therapy.

Document prior supervised lifestyle therapy and reason for proceeding to IGB
If contraindication to step therapy exists, provide supporting rationale

Documentation Required

Concomitant lifestyle therapy

Trials of IGBs in RCTs included concomitant intensive lifestyle modification and counseling. Providers should document plans for moderate- to high-intensity lifestyle interventions (nutrition, physical activity, behavioral counseling) concurrent with device therapy.

Provide counseling schedule and responsible providers (dietitian, behavioral health)
Document patient agreement to follow-up visits and program participation

Step Therapy

Step therapy consideration

Step therapy consideration more broadly: prior authorization may require documentation of failure or contraindication to less invasive options (diet, activity, behavioral therapy, pharmacotherapy) before approving device implantation or major revisional surgery.

Provide documented timeline of prior therapies and outcomes
Explain contraindications when step therapy is bypassed

Step Therapy

Conservative therapy before device/surgery

Conservative therapy should generally be attempted prior to device placement or bariatric surgery unless clinically contraindicated. Document the type, duration, and outcomes of conservative interventions tried.

Document behavioral programs, pharmacotherapy, and supervised diet/exercise participation
Provide reasons for proceeding to procedural therapy

Billing Rule

Coding documentation note

Coding clarification: use CPT 43775 to report laparoscopic sleeve gastrectomy rather than unlisted CPT 43659. Include appropriate CPT/ICD-10 codes and modifiers per billing guidance.

CPT 43775 for laparoscopic sleeve gastrectomy
Avoid unlisted CPT 43659 when 43775 applies

Documentation Required

Adverse event documentation for IGB/DBS

Document device-specific adverse events for intragastric balloons and implantable devices (for example: balloon deflation, gastric ulcers, intolerance requiring early removal, device migration, lead failure, implant-site pain, hepatic abscess, gastrointestinal hemorrhage). Include dates, management, and outcomes in the record.

Record event type, onset date, interventions performed, and resolution status
Document any device removals and reasons

Documentation Required

Postoperative monitoring for OAGB/MGB

Postoperative monitoring is required for procedures with malabsorptive potential such as OAGB/MGB. Monitor for GERD symptoms, diarrhea/steatorrhea, and nutritional deficiencies; document surveillance plans and any supplementation prescribed.

Plan for micronutrient monitoring and supplementation
Monitor and document GI symptoms (GERD, diarrhea, steatorrhea)

Documentation Required